Active, not recruitingNCT05227287
ADH1 and ADH2 Disease Monitoring Study (DMS)
Studying Autosomal dominant hypocalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Principal Investigator
- Calcilytix Medical DirectorCalcilytix Therapeutics, Inc., a BridgeBio company
- Enrollment
- 95 enrolled
- Eligibility
- 90 years · All sexes
- Timeline
- 2022 – 2028
Study locations (27)
- University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- Indiana University (IU) School of Medicine - University Hospital, Indianapolis, Indiana, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Physician's East Endocrinology, Greenville, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Ohio State University Medical Center (OSUMC), Columbus, Ohio, United States
- Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
- Universitaire Ziekenhuizen Leuven, Leuven, Flemish Brabant, Belgium
- Bone Research and Education Centre, Oakville, Ontario, Canada
- Aarhus University Hospital, Aarhus, Denmark
- Helsinki University Hospital (HUS) - The New Children's Hospital, Helsinki, Finland
- HCL Hopital Femme Mere Enfant, Bron, Auvergne-Rhône-Alpes, France
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05227287 on ClinicalTrials.govOther trials for Autosomal dominant hypocalcemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07428057Postoperative Hypocalcemia After ThyroidectomyMinia University
- RECRUITINGPHASE2, PHASE3NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT05680818Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Calcilytix Therapeutics, Inc., a BridgeBio company